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© 2011 The Japan Society of Histochemistry and Cy- Thalidomide is clinically recognized as a therapeutic agent for multiple myeloma and has
been known to exert anti-angiogenic actions. Recent studies have suggested the involve-
ment of angiogenesis in the progression of peritoneal fibrosis. The present study investi-
gated the effects of thalidomide on the development of peritoneal fibrosis induced by injec-
tion of chlorhexidine gluconate (CG) into the mouse peritoneal cavity every other day for 3
weeks. Thalidomide was given orally every day. Peritoneal tissues were dissected out 21
days after CG injection. Expression of CD31 (as a marker of endothelial cells), proliferating
cell nuclear antigen (PCNA), vascular endothelial growth factor (VEGF), α-smooth muscle
actin (as a marker of myofibroblasts), type III collagen and transforming growth factor
(TGF)-β was examined using immunohistochemistry. CG group showed thickening of the
submesothelial zone and increased numbers of vessels and myofibroblasts. Large numbers
of VEGF-, PCNA-, and TGF-β-positive cells were observed in the submesothelial area.
Thalidomide treatment significantly ameliorated submesothelial thickening and angiogenesis,
and decreased numbers of PCNA- and VEGF-expressing cells, myofibroblasts, and TGF-
β-positive cells. Moreover, thalidomide attenuated peritoneal permeability for creatinine,
compared to the CG group. Our results indicate the potential utility of thalidomide for
preventing peritoneal fibrosis.
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I. Introduction
Peritoneal dialysis (PD) is a beneficial therapy for end-
stage renal disease in terms of preserving residual renal
function and improving hemodynamic stability, but long-
term PD therapy causes histopathological and functional
changes in the peritoneum, such as peritoneal fibrosis
with increased submesothelial collagen deposition, loss of
mesothelial cells and ultrafiltration failure [6, 10, 13].
Williams et al. demonstrated a correlation between perito-
neal vascular density and peritoneal fibrosis in patients on
long-term PD [33]. Furthermore, Honda et al. [15] reported
that the appearance of vasculopathy correlated with reduc-
tions in ultrafiltration. Other studies have shown that the
concentration of vascular endothelial growth factor (VEGF)
in peritoneal fluid is up-regulated in PD patients [37, 38].
These findings suggest that angiogenesis is also associated
with the pathogenesis of peritoneal fibrosis and peritoneal
dysfunction.
To elucidate the mechanism of peritoneal fibrosis, it
would be useful to utilize convenient and reproducible
experimental animal models [23, 35]. Of these, we used a
mice model in the present study, which may be a more useful
experimental model for studies examining immune system
involvement in disease progression because of the avail-
ability of histopathological and cytological antibodies,
therapeutic agents, and genetically engineered mice [17].Arai et al. 52
Although the mechanisms underlying the development
of peritoneal fibrosis by chlorhexidine gluconate (CG) are
unclear, research has shown that persistent chemical irri-
tation by CG induces tissue damage with inflammation,
followed by tissue repair with excessive proliferation of
fibroblasts [23]. In addition, we have demonstrated that the
number of blood vessels also increases during the progres-
sion of CG-induced peritoneal fibrosis [23, 27, 35]. These
changes resemble those seen in the peritoneum of long-term
PD patients.
Yoshio et al. recently demonstrated that TNP-470, an
anti-angiogenic compound, markedly reduced the number of
blood vessels and myofibroblasts and suppressed the pro-
gression of CG-induced peritoneal fibrosis in an experimen-
tal mouse model [35]. In addition, Io et al. demonstrated a
reduction in peritoneal-associated vessels and suppression
of peritoneal fibrosis by anti-VEGF neutralizing antibody
injection in a rat peritoneal fibrosis model induced by CG
injection [16]. These results suggest that anti-angiogenic
therapies or drugs might limit or prevent the progression of
peritoneal fibrosis in patients with long-term PD.
Thalidomide, α-N-phthalidoglutarimide ((C13H10N2)4),
was originally marketed as a sedative and anti-emetic, but
was withdrawn following the identification of severe terato-
genic effects [5]. The mechanisms of action for thalidomide
are complex and probably include different molecular
targets. D’Amato et al. have reported that thalidomide
inhibits angiogenesis by interrupting processes mediated
by basic fibroblast growth factor (bFGF) and/or VEGF [8].
Thalidomide may thus exert potent immunomodulatory,
anti-angiogenic, and anti-proliferative actions. Indeed, the
ability of thalidomide to inhibit angiogenesis was confirmed
in a rabbit cornea micropocket assay [8]. Furthermore, the
antifibrotic effects of thalidomide have been reported in
animal models of bleomycin-induced pulmonary fibrosis
[32], liver cirrhosis [19–21, 29], myocardial infarction [34],
and peritoneal fibrosis [25].
The present study investigated the effects of thalido-
mide, which has anti-angiogenic and anti-proliferative ac-
tions, on the progression of peritoneal fibrosis using a mouse
model of peritoneal fibrosis induced by CG injection.
II. Materials and Methods
Animals
Male ICR mice (Japan SLC, Shizuoka, Japan) at 8
weeks old (body weight, 25±3 g) were used in the present
study. Animals were housed in a light- and temperature-
controlled room in the Biomedical Research Center of the
Center for Frontier Life Sciences at Nagasaki University.
They had free access to laboratory chow and tap water in
standard rodent cages. Based on the national regulations and
guidelines, all experimental procedures were reviewed by
Institutional Animal Care and Use Committee of Nagasaki
University and finally approved by the president (No.
0605220510).
Experimental protocol
Peritoneal fibrosis was induced by intraperitoneal in-
jection of 0.1% CG in 15% ethanol dissolved in saline, as
described previously with some modifications [27, 35].
Mice received injections of CG into the peritoneal cavity at
a volume of 10 mL/kg body weight every other day for 3
weeks. Mice were divided into four groups (n=5 each).
The CG group received injections of CG into the peritoneal
cavity and oral vehicle (methylcellulose) 5 times/week
for 3 weeks. The CG+thalidomide group received oral
thalidomide (kindly donated by Fujimoto Pharmaceutical
Corp., Osaka, Japan) 5 times/week with CG for 3 weeks.
The control group was injected intraperitoneally with 15%
ethanol in saline and given oral vehicle. The thalidomide
group was injected intraperitoneally with 15% ethanol in
saline and given oral thalidomide. Dose and interval for oral
administration of thalidomide were selected based on pilot
studies conducted to determine the effects of different doses
on thickness of the submesothelial area. Thalidomide doses
<10 mg/kg did not reduce peritoneal thickness compared
with untreated CG group, so we selected a dose of 10 mg/kg
administered 5 times/week for the present study. Injection
of 0.1% CG was performed under ether anesthesia to ensure
injection of the correct dose at the correct site, and to avoid
induction of pain during intraperitoneal injection. Mice were
sacrificed at 2 or 3 weeks just after the peritoneal function
test, and peritoneal tissues were carefully dissected out. To
avoid direct damage to the peritoneum caused by repeated
injections, CG injections were made into the lower part of
the peritoneum, while the upper portion of the parietal
peritoneum was used for examination. Tissues were fixed
with 4% paraformaldehyde immediately after sampling and
embedded in paraffin.
Histological and immunohistochemical examination
For morphological examination, 4-μm thick paraffin-
embedded tissues were stained with hematoxylin and eosin
(HE). The immunohistochemical procedure used in the
present study was described previously [1, 31]. The fol-
lowing antibodies were used for immunohistochemistry:
1) goat anti-mouse CD31 antibody diluted 1/50 (sc-1506;
Santa Cruz Biotechnology, Santa Cruz, CA, USA), as a
marker for endothelial cells; 2) mouse anti-proliferative cell
nuclear antigen (PCNA) antibody diluted 1/200 (M0879;
Dako, Glostrup, Denmark), as a marker for proliferative
cells; 3) mouse anti-human α-smooth muscle actin (SMA)
antibody diluted 1/100 (M0851; Dako), as a marker for
myofibroblasts; 4) rabbit anti-human transforming growth
factor (TGF)-β antibody diluted 1/100 (sc-146; Santa Cruz
Biotechnology); 5) rabbit anti-rat type III collagen antibody
diluted 1/400 (LB1393; LSL, Tokyo, Japan); and 6) rabbit
anti-human VEGF antibody diluted 1/50 (sc-507; Santa
Cruz Biotechnology).
To block endogenous peroxidase, renal sections were
reacted with methanol containing 0.3% H2O2 for 15 min at
room temperature. An indirect immunohistochemical tech-
nique was used for PCNA, type III collagen and α-SMA.Thalidomide Prevents Peritoneal Fibrosis 53
For PCNA, deparaffinized tissue sections were incubated
for 30 min with a blocking buffer containing normal goat
immunoglobulin G (IgG) (I9140; Dako) diluted 1/20 by 1%
bovine serum albumin (BSA) in phosphate-buffered saline
(PBS), then reacted with anti-PCNA antibody in 1% BSA/
PBS for 2 hr at room temperature. After reacting with
primary antibody, sections were reacted with horseradish
peroxidase (HRP)-conjugated goat anti-mouse immuno-
globulin antibody (P0447; Dako) diluted 1/100 for 1 hr at
room temperature. For type III collagen, deparaffinized
tissue sections were incubated for 30 min with a blocking
buffer containing 5% normal goat serum, 5% fetal calf
serum, 5% BSA, and 20% normal swine serum in PBS.
Sections were then reacted with the primary antibody
diluted in the same blocking buffer. After reacting with
anti-type III collagen antibody for 1 hr at room tempera-
ture, sections were reacted with HRP conjugated swine anti-
rabbit immunoglobulin antibody (P0399; Dako) diluted
1/50 for 30 min and at room temperature, and peroxidase
anti-peroxidase antibody (Z0113; Dako) diluted 1/100 for
30 min at room temperature. For α-SMA, sections were
reacted with a complex of anti-α-SMA antibody and HRP-
conjugated rabbit anti-mouse immunoglobulin antibody
(Z0109; Dako) diluted 1/100 for 1 hr at room temperature,
and HRP-labeled dextran polymer-conjugated goat anti-
rabbit immunoglobulin antibody (K4002; Dako) for 30
min at room temperature. For CD31, VEGF and TGF-β, we
applied  the  peroxidase  and  avidin-biotin-complex  tech-
nique using Vectastain Elite ABC kit (Vector Laboratories,
Burlingame, CA, USA), after reacting with primary anti-
bodies for 16 hr at 4°C. Reaction products were visualized
by treating sections with H2O2 and 3,3'-diaminobenzidine
tetrahydrochloride (DAB). Finally, sections were counter-
stained with methyl green and mounted. For all specimens,
negative controls were prepared with irrelevant mouse
monoclonal antibody, rat monoclonal antibody, normal goat
IgG, or normal rabbit IgG in place of the primary antibody.
Terminal deoxynucleotidyl transferase (TdT)-mediated dUTP 
nick end-labeling (TUNEL) staining
To identify apoptotic cells, TUNEL was performed
according to the method of Gavrieli et al. [14] with a slight
modification [9]. Paraffin sections (5–6 μm in thickness) on
silane-coated glass slides were dewaxed and digested with
10 μg/ml of proteinase K in PBS at 37°C for 15 min. The
sections were then incubated with TdT buffer (25 mM Tris/
HCl buffer, pH 6.6, containing 0.2 M potassium cacodylate
and 0.25 mg/ml BSA) at room temperature for 30 min.
After incubation, the slides were reacted with 800 U/ml of
TdT dissolved in TdT buffer supplemented with 0.5 μM
biotin-16-dUTP, 20 μM dATP, 1.5 mM CoCl2 and 0.1 mM
dithiothreitol at 37°C for 90 min. After washing with
double-distilled water, signals were detected immuno-
histochemically using HRP-conjugated goat anti-biotin anti-
body. HRP sites were visualized with a mixture of DAB, hy-
drogen peroxide, nickel and cobalt ions.
Peritoneal function test (PET)
A PET was used to investigate peritoneal permeability
parameters in mice, as described previously [26]. After
anesthesia, a silicon catheter was inserted into the peritoneal
cavity and 8.0 ml of a standard dialysate (Dianeal®; Baxter
International Inc., Deerfield, IL, USA) containing 2.5%
glucose was instilled. Blood and dialysate samples were
taken at 60 min after administration of dialysate. Transport
of small solutes was evaluated using the dialysate-to-plasma
(D/P) ratio of creatinine.
Morphometric analysis
We used image analysis software (Lumina Vision,
Mitani Corp., Tokyo, Japan) on digitized images to assess
the extent of peritoneal thickening. We measured the
thickness of the submesothelial compact zone above the
abdominal muscle in cross-sections of the abdominal wall.
The image was transformed into a matrix of 1280×1000
pixels and viewed at ×200 magnification. We selected a
width of 840 μm in the field examined under the microscope
and measured the area of the submesothelial layer within
the selected width of 840 μm. For each sample, 10 such
areas were selected and the average area of the submeso-
thelial layer was determined. In each peritoneal sample,
numbers of CD31-positive vessels, PCNA-positive cells,
VEGF-expressing cells, α-SMA-expressing cells, and TGF-
β-expressing cells, and were counted in 10 fields at ×200
magnification.
Statistical analysis
Data are expressed as mean±standard error of the
mean (SEM). Differences among groups were examined for
statistical significance using repeated-measures analysis of
variance and the Bonferroni/Dunn test. Values of P<0.05
denoted the presence of a statistically significant difference.
III. Results
Morphological examination
Morphological changes were assessed by HE staining.
In normal mice, peritoneal tissue comprises a peritoneal
mesothelial monolayer and sparse connective tissues under
the mesothelial layer (Fig. 1A). CG injection gradually
induced exacerbation of peritoneal fibrosis (Fig. 1B, C). At
3 weeks, peritoneal samples from mice in the CG group
showed marked thickening of the submesothelial compact
zone and the presence of numerous cells (Fig. 1C). In the
CG+thalidomide group, the thickness of the submesothelial
compact zone and the number of infiltrating cells were
significantly less than in the CG group (Fig. 1D). Peritoneal
tissues in control mice were almost normal without any
thickening of the submesothelial zone (data not shown).
Repeated administration of thalidomide alone did not affect
the thickening of the peritoneum compared with controls
(data not shown). In addition, the severity of submesothelial
area thickening in mice injected with CG and the vehicle
used to dissolve thalidomide was similar to that in CG-Arai et al. 54
injected mice (data not shown). The results of semi-
quantitative analysis of the area of the submesothelial
compact zone in each group are shown in Figure 1E.
Expression of CD31
Recent studies have described the presence of an
increased number of vessels in thickened peritoneal tissues
of both peritoneal dialysis patients [33] and experimental
models of peritoneal fibrosis [35]. Meanwhile, several
recent studies have indicated that thalidomide has anti-
angiogenic actions. To examine the effect of thalidomide
on the vasculopathy observed in peritoneal fibrosis model,
the number of blood vessels was quantified using immuno-
histochemistry for CD31. The number of CD31-positive
vessels was markedly increased in mice from the CG group
(Fig. 2A). In contrast, thalidomide administration decreased
the number of CD31-expressing vessels (Fig. 2B). Table 1
summarizes the results of quantitative analysis of CD31-
positive vessels in the submesothelial compact zone.
Expression of PCNA
To examine whether thalidomide exerts anti-prolifera-
tive effects on the process of peritoneal fibrosis, PCNA
staining was performed. Treatment with CG resulted in
the appearance of numerous PCNA-positive cells in the
thickened submesothelial area (Fig. 2C). Those cells com-
prised peritoneal mesothelial cells, fibroblast-like spindle-
shaped cells, and vascular endothelial cells. Compared with
Fig. 1. Hematoxylin and eosin staining of peritoneal tissues. In normal mice, the
monolayer of mesothelial cells covers the entire surface of the peritoneum (A). At
2 weeks, chlorhexidine gluconate (CG) injection has gradually induced peritoneal
fibrosis (B). At 3 weeks, CG injection induced significant thickening of the perito-
neum (C). Administration of thalidomide in CG-treated mice significantly sup-
pressed the progression of peritoneal thickening at a concentration of 10 mg/kg (D).
Bars, area of the submesothelial compact zone. Magnification: ×100. Mean area of
the submesothelial compact zone in the CG and CG+thalidomide groups at concen-
trations of 3, 10 and 20 mg/kg (E). Data are presented as the mean±SEM. Sub-
mesothelial area in the CG group was significantly increased, while administration
of thalidomide significantly reduced the progression of submesothelial thickening
in CG+thalidomide groups (10 and 20 mg/kg) compared with the CG group.
*P<0.05 versus CG, #P<0.05 versus 3 mg.Thalidomide Prevents Peritoneal Fibrosis 55
Fig. 2. Immunohistochemistry for CD31, PCNA, VEGF, and TUNEL. Note the presence of numerous vessels positively stained for CD31
(arrows) in the CG group (A), while few vessels are stained for CD31 (arrows) in the CG+thalidomide group (B). Magnification: ×200. Note the
presence of cells staining positively for PCNA in the CG group (C), while few cells stain for PCNA in the CG+thalidomide group (D). Magni-
fication: ×200. Note the large number of VEGF-expressing cells in the CG group (E). Thalidomide treatment markedly decreased the number of
these cells (F) in the thickened submesothelial zone. Magnification: ×200. Note the presence of TUNEL positive cells in the CG group and
CG+thalidomide group (G and H). The number of TUNEL positive cells in the CG+thalidomide group was as same as that in the CG group.
Magnification: ×200.Arai et al. 56
the CG group, treatment with thalidomide significantly
reduced the number of PCNA-expressing cells, particularly
vascular endothelial cells (Fig. 2D).
Expression of VEGF
Previous investigations have suggested the involve-
ment of VEGF in the vasculopathy seen with peritoneal
fibrosis [7, 16]. To examine the mechanisms of action for
thalidomide on vasculopathy, the expression of VEGF in the
CG group was compared with that in the CG+thalidomide
group. In the control group, VEGF was expressed in the
peritoneal mesothelial monolayer (data not shown). In
the CG group, the number of VEGF-expressing cells was
markedly increased compared with controls (Fig. 2E).
Conversely, peritoneal tissues from the CG+thalidomide
group contained fewer VEGF-expressing cells compared
with the CG group (Fig. 2F). Table 1 summarizes the results
of quantitative analysis of VEGF-positive vessels in the
submesothelial compact zone.
Involvement of apoptosis
To clarify the involvement of apoptosis in CG-induced
peritoneal fibrosis, TUNEL staining was performed. The
number of TUNEL-positive cells was not different between
the CG and CG+thalidomide groups. (Fig. 2G, H).
Expression of α-SMA and type III collagen
The results of immunohistochemical analyses for α-
SMA and type III collagen are shown in Figure 3 and
Table 1. In the control group, expression of α-SMA was
only observed in vascular smooth muscle cells (data not
shown). In contrast, the CG group showed α-SMA expres-
sion in myofibroblasts in addition to vascular smooth
muscle cells, and numerous α-SMA-expressing myofibro-
blasts were identified in the thickened peritoneal tissues
(Fig. 3A). Compared with the CG group, the number of
α-SMA-positive myofibroblasts was markedly reduced in
the CG+thalidomide group (Fig. 3B). We also investigated
peritoneal expression of type III collagen by immuno-
histochemistry. In the CG group, type III collagen was
diffusely expressed in the submesothelial zone (Fig. 3C),
while thalidomide treatment reduced type III collagen
expression (Fig. 3D).
Expression of TGF-β
TGF-β is widely known as an important mediator for
progressing fibrosis. In addition, a previous report showed
that increased expression of TGF-β was associated with
the extent of peritoneal fibrosis [22]. To examine whether
thalidomide influenced the expression of TGF-β, the ex-
pression  of  TGF-β  was  examined  immunohistochemically.
The number of TGF-β-positive cells was increased in the
thickened peritoneum in the CG group (Fig. 3E), but was
markedly reduced in the CG+thalidomide group (Fig. 3F,
Table 1).
Peritoneal transport study
To investigate the effects of thalidomide on transport
across the peritoneum, PET adapted for mice was evaluated
[26]. CG treatment induced a major increase in permeability
for creatinine, compared to that in control mice. In contrast,
this modification was significantly attenuated with thalido-
mide treatment (Fig. 4).
IV. Discussion
The present study shows that administration of thalido-
mide attenuates both CG-induced angiogenesis and CG-
induced collagen accumulation in the thickened subme-
sothelial area in an experimental mouse model of peritoneal
fibrosis. Moreover, peritoneal transport studies demon-
strated that small solute transport was promoted in the CG
group, and that this increase in permeability was inhibited
by thalidomide administration. These findings indicate
that thalidomide attenuates both structural and functional
damage of peritoneum in peritoneal fibrosis induced by CG
and that thalidomide is potentially useful for preventing peri-
toneal fibrosis.
Concerning the mechanisms by which thalidomide in-
hibits angiogenesis in this model, analysis has focused on
the effect of thalidomide on the expression of VEGF. VEGF
is known to play an important role in endothelial cell pro-
liferation, vascular permeability, and angiogenesis in several
inflammatory lesions and tumors [13, 24]. To date, VEGF
expression has been confirmed to be up-regulated by various
stimuli, such as low oxygen tension, cytokines, and TGF-β
[11, 12]. Furthermore, several studies have shown that the
concentration of VEGF in peritoneal fluid is increased in
PD patients [38]. The present investigation demonstrated
increased expression of VEGF in the submesothelial com-
pact zone for the CG group compared with the control
group, and this increase was significantly attenuated in the
CG+thalidomide group. These results suggest that, in the
present model, angiogenesis was attenuated through the
inhibition of VEGF expression by thalidomide.
With respect to the inhibitory effect of thalidomide on
CG-induced collagen accumulation, we must focus attention
on the inhibitory effects of thalidomide both on the prolifer-
Table 1. Number of positive cells of immunohistochemistry for
CD31, PCNA, VEGF, α-SMA, and TGF-β in the peritoneum
Data are given as mean±SEM. The numbers of CD31-positive vessels,
VEGF-expressing cells, PCNA-positive vessels, α-SMA-expressing
cells, and TGF-β-expressing cells were determined in 10 fields of the
submesothelial region selected at random in each mouse and examined
at ×200 magnification. aP<0.05 versus CG group.
CG group CG+thalidomide group
CD31 21±3 4±1a
PCNA 19±3 11±2a
VEGF 103±9 65±6a
α-SMA 61±4 41±4a
TGF-β 148±7 89±5aThalidomide Prevents Peritoneal Fibrosis 57
ation of myofibroblasts and on the expression of TGF-β.
Several studies have demonstrated that TGF-β is a profibrot-
ic factor that increases fibroblast proliferation, stimulates
the synthesis and deposition of extracellular matrix (ECM),
and inhibits ECM breakdown [30]. In addition, TGF-β pro-
motes epithelial-to-mesenchymal transition (EMT) [18] and
transdifferentiation of fibroblasts into myofibroblasts, which
are the main cells producing collagen [30]. Our results
showed that the number of TGF-β-positive cells decreased
in the CG+thalidomide group together with a reduction in
“α-SMA-positive” myofibroblasts and collagen accumula-
tion in the submesothelial area. These data support the
hypothesis that thalidomide inhibits collagen accumulation
by anti-proliferative effects on myofibroblasts and by down-
regulatory effects on the expression of TGF-β in myofibro-
blasts. In addition, the expression of heat shock protein
47 (HSP47), a molecular chaperone that is essential for
collagen secretion and formation, was increased in the CG
group but was reduced by thalidomide administration (data
not shown). Moreover, thalidomide has been reported to
Fig. 3. Immunohistochemistry for α-SMA, type III collagen, and TGF-β. In the CG group, note the presence of a large number of α-SMA-
positive cells in the submesothelial zone (A). The number of α-SMA-positive cells is reduced in the CG+thalidomide group (B). In the CG
group, type III collagen is strongly expressed in the submesothelial compact zone (C), but is clearly decreased in the CG+thalidomide group
(D). Note the strong expression of TGF-β in the thickened submesothelial in the CG group (E), while such expression is decreased in the
CG+thalidomide group (F). Magnification: ×200.Arai et al. 58
suppress expression of metalloproteinase (MMP)-2 and
MMP-9, which are involved in collagen degradation, in vitro
and in melanoma tumors [36]. Based on the above, the
mechanism by which thalidomide attenuates CG-induced
type III collagen accumulation was thought to involve not
the promotion of collage degradation, but a decrease in col-
lagen synthesis as well as suppression of collagen secretion
and formation associated with reduced TGF-β and HSP47
expression.
The various factors investigated herein using the
enzyme-labeled antibody technique showed different distri-
butions between the shallow and deep areas of the sub-
mesothelial compact zone. CG administration resulted in
increased expression of vascular endothelial cells (CD31-
positive cells), myofibroblasts, and TGF-β-positive cells in
the deep area of the submesothelial compact zone, while
the number of these cells decreased following thalidomide
administration. With regard to the mechanisms underlying
these changes, we investigated the possibility of apoptosis-
inducing effects of thalidomide using the TUNEL method.
However, as no differences were observed in the number of
TUNEL-positive cells, the involvement of apoptosis was
ruled out. Therefore, it was conjectured that the inhibitory
effect of thalidomide on angiogenesis and myofibroblast
proliferation observed in the present study was attributable
to suppression of VEGF and TGF-β expression caused by
the inhibition of nuclear factor (NF)-κB activation by thali-
domide [25]. Meanwhile, PCNA- and VEGF-positive cells
were distributed in the shallow area of the submesothelial
compact zone in the CG group. Previously, it was reported
that TGF-β, TNF-α, and other inflammatory cytokines
produced by CG administration resulted in differentiation
of mesothelial cells into highly proliferative mesenchymal
cells and that these transdifferentiated cells increase the
expression of VEGF [2]. Furthermore, it is well known that
thalidomide exerts its anti-inflammatory effect through the
inhibition of EMT inducers such as TGF-β and TNF-α [28].
These findings suggested that the induction of EMT on
mesothelium might contribute to distribution of PCNA- and
VEGF-positive cells near the surface of the peritoneum in
the CG group and decreases in the numbers of the afore-
mentioned cells in the thalidomide group.
More recently, Mondello et al. demonstrated that
treatment with thalidomide reduced the degree of peritoneal
fibrosis in a rat model of peritoneal fibrosis induced by CG.
They also showed that thalidomide reduced the expression
of VEGF and TGF-β in thickened peritoneal tissue and in-
hibited NF-κB activation [25]. Concerning the anti-fibrotic
effects of thalidomide, our results are in line with those
reported by Mondello et al. However, the amount of thalido-
mide used in our study (10 mg/kg/day) was substantially
smaller than that used in the study reported by Mondello et
al. (100 mg/kg orally, 3 times/week). In addition, the effects
of thalidomide treatment on peritoneal function have yet to
be clarified in the previous paper [25].
From the perspective of safety, thalidomide can have
severe adverse effects in a dose-dependent manner. In gen-
eral, most animal experiments, including that by Mondello
et  al.,  have  required  relatively  high  doses  (100–200
mg/kg/day) to achieve beneficial effects of thalidomide,
due to the short half-life of this drug [25]. In contrast, em-
phasis needs to be placed on the finding that thalidomide in
the present study was effective in suppressing peritoneal
fibrosis at a low dose (10 mg/kg/day) close to doses current-
ly used in clinical situations. The anti-fibrotic effects of
thalidomide seen with administration of a much lower dose
could reasonably be considered likely to help in mini-
mizing adverse effects and may lead to clinical applications
in the future.
Since the capacity for ultrafiltration across the perito-
neal membrane is well known as a major predictor of
outcome and mortality in PD patients [3, 4], the efficacy of
thalidomide on peritoneal function was examined using a
transport study. CG treatment induced a major increase in
permeability for creatinine, and this modification was in turn
attenuated in the CG+thalidomide group. These data indi-
cate that thalidomide treatment, through inhibition of VEGF,
exerts not only anti-angiogenic effects, but also protective
effects on the increase in peritoneal permeability in regard to
peritoneal function.
In conclusion, these findings indicate that thalidomide
might be useful in preventing the progression of peritoneal
fibrosis and the alteration of peritoneal function by inhibit-
ing both angiogenesis and collagen accumulation.
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Fig. 4. Transport study. CG treatment induced a major increase in
the permeability for creatinine. In contrast, this modification was
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